BACKGROUND AND PURPOSE: alpha-Humulene and trans-caryophyllene are sesquiterpene compounds identified in the essential oil of Cordia verbenacea which display topical and systemic anti-inflammatory effects in different experimental models. However, the molecular mechanisms through which they exert their anti-inflammatory activity still remain unclear. Here, we evaluate the effects of alpha-humulene and trans-caryophyllene on the acute inflammatory responses elicited by LPS. EXPERIMENTAL APPROACH: The biological activities of alpha-humulene and trans-caryophyllene were investigated in a model of acute inflammation in rat paw, induced by LPS and characterized by paw oedema, neutrophil recruitment, cytokine production, activation of MAP kinases and NF-kappaB and up-regulated expression of kinin B(1) receptors. KEY RESULTS: Treatment with either alpha-humulene or trans-caryophyllene effectively reduced neutrophil migration and activation of NF-kappaB induced by LPS in the rat paw. However, only alpha-humulene significantly reduced the increase in TNF-alpha and IL-1beta levels, paw oedema and the up-regulation of B(1) receptors following treatment with LPS. Both compounds failed to interfere with the activation of the MAP kinases, ERK, p38 and JNK. CONCLUSIONS AND IMPLICATIONS: Both alpha-humulene and trans-caryophyllene inhibit the LPS-induced NF-kappaB activation and neutrophil migration, although only alpha-humulene had the ability to prevent the production of pro-inflammatory cytokines TNF-alpha and IL-1beta and the in vivo up-regulation of kinin B(1) receptors. These data provide additional molecular and functional insights into the beneficial effects of the sesquiterpenes alpha-humulene and trans-caryophyllene isolated from the essential oil of Cordia verbenacea as agents for the management of inflammatory diseases.
BACKGROUND AND PURPOSE:alpha-Humulene and trans-caryophyllene are sesquiterpene compounds identified in the essential oil of Cordia verbenacea which display topical and systemic anti-inflammatory effects in different experimental models. However, the molecular mechanisms through which they exert their anti-inflammatory activity still remain unclear. Here, we evaluate the effects of alpha-humulene and trans-caryophyllene on the acute inflammatory responses elicited by LPS. EXPERIMENTAL APPROACH: The biological activities of alpha-humulene and trans-caryophyllene were investigated in a model of acute inflammation in rat paw, induced by LPS and characterized by paw oedema, neutrophil recruitment, cytokine production, activation of MAP kinases and NF-kappaB and up-regulated expression of kinin B(1) receptors. KEY RESULTS: Treatment with either alpha-humulene or trans-caryophyllene effectively reduced neutrophil migration and activation of NF-kappaB induced by LPS in the rat paw. However, only alpha-humulene significantly reduced the increase in TNF-alpha and IL-1beta levels, paw oedema and the up-regulation of B(1) receptors following treatment with LPS. Both compounds failed to interfere with the activation of the MAP kinases, ERK, p38 and JNK. CONCLUSIONS AND IMPLICATIONS: Both alpha-humulene and trans-caryophyllene inhibit the LPS-induced NF-kappaB activation and neutrophil migration, although only alpha-humulene had the ability to prevent the production of pro-inflammatory cytokines TNF-alpha and IL-1beta and the in vivo up-regulation of kinin B(1) receptors. These data provide additional molecular and functional insights into the beneficial effects of the sesquiterpenesalpha-humulene and trans-caryophyllene isolated from the essential oil of Cordia verbenacea as agents for the management of inflammatory diseases.
Authors: Marie Eve Moreau; Nancy Garbacki; Giuseppe Molinaro; Nancy J Brown; François Marceau; Albert Adam Journal: J Pharmacol Sci Date: 2005-09 Impact factor: 3.337
Authors: Rachel K Conley; Alan Wheeldon; Janine K Webb; Robert M DiPardo; Carl F Homnick; Mark G Bock; Tsing-Bau Chen; Raymond S L Chang; Douglas J Pettibone; Susan Boyce Journal: Eur J Pharmacol Date: 2005-11-28 Impact factor: 4.432
Authors: F Porreca; T W Vanderah; W Guo; M Barth; P Dodey; V Peyrou; J M Luccarini; J-L Junien; D Pruneau Journal: J Pharmacol Exp Ther Date: 2006-03-24 Impact factor: 4.030
Authors: Giselle F Passos; Elizabeth S Fernandes; Fernanda M da Cunha; Juliano Ferreira; Luiz F Pianowski; Maria M Campos; João B Calixto Journal: J Ethnopharmacol Date: 2006-11-03 Impact factor: 4.360
Authors: Ana C C Rocha; Elizabeth S Fernandes; Giselle F Passos; João B Calixto; Maria M Campos Journal: Int Immunopharmacol Date: 2005-10 Impact factor: 4.932
Authors: Mariem El Sayah; Rodrigo Medeiros; Elizabeth S Fernandes; Maria M Campos; João B Calixto Journal: Mol Pharmacol Date: 2006-02-07 Impact factor: 4.436
Authors: Gabriella Aviello; Francesca Borrelli; Francesca Guida; Barbara Romano; Kevin Lewellyn; Maria De Chiaro; Livio Luongo; Jordan K Zjawiony; Sabatino Maione; Angelo A Izzo; Raffaele Capasso Journal: J Mol Med (Berl) Date: 2011-04-16 Impact factor: 4.599
Authors: Cristina P B Melo; Priscila Saito; David L Vale; Camilla C A Rodrigues; Ingrid C Pinto; Renata M Martinez; Julia R Bezerra; Marcela M Baracat; Waldiceu A Verri; Yris Maria Fonseca-Bazzo; Sandra R Georgetti; Rubia Casagrande Journal: Photochem Photobiol Sci Date: 2021-07-23 Impact factor: 3.982
Authors: Alexandre P Rogerio; Edinéia L Andrade; Daniela F P Leite; Cláudia P Figueiredo; João B Calixto Journal: Br J Pharmacol Date: 2009-05-08 Impact factor: 8.739
Authors: Magaiver Andrade-Silva; Luana Barbosa Correa; André Luis Peixoto Candéa; Simone C Cavalher-Machado; Helene Santos Barbosa; Elaine Cruz Rosas; Maria G Henriques Journal: Inflamm Res Date: 2016-07-05 Impact factor: 4.575